Author: PharmaSignal News Desk

Cytokinetics FDA approval marks a milestone with Myqorzo, challenging Bristol Myers’ Camzyos in the heart drug market.

Merck Daiichi FDA hold impacts ADC trial for small cell lung cancer due to unexpected patient deaths.

Novo Nordisk has filed for approval of its obesity drug CagriSema.

Novo Nordisk oral Wegovy receives FDA approval, marking a significant step in the obesity drug market.

Cytokinetics FDA approval marks a milestone with Myqorzo, challenging Bristol Myers’ Camzyos in the heart drug market.

Merck and Daiichi Sankyo’s I-DXd trial faces FDA hold due to unexpected death rates in small cell lung cancer study.

BioMarin Amicus acquisition for $4.8B adds a late-stage asset and two marketed therapies generating $450M in nine months.

Novo Nordisk FDA approval for oral Wegovy marks a significant step in the obesity drug market, outpacing competitors.

Biopharma CEO optimism varies globally, with US executives showing less confidence. Survey reveals differences in outlook.

Drug price deals with Trump involve 9 drugmakers, impacting tariffs and benefits. Analysts see limited financial effect.